SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Shorts
XOMA 32.98-0.7%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Terry who wrote (46)12/22/1997 11:45:00 AM
From: Jim Roof  Read Replies (1) of 61
 
The salt solutions are cheap but make you swell up like a bloated pig and put strain and stress on the renal system. The current hespan products that are the most similar to Hextend do not address clotting issues. They work better than salts but are still lacking. Transfused blood carries with it the baggage of disease potential and perhaps as important, the time required for typing and matching. Albumin is very costly (about 600/ltr).

From what I hear from the phase III trials, Hextend performed well - better than expected according to some and it produced less bleeding than the control group. These are all positives.

It might be worth noting that Hextend actually was not the target of Biotime's intial business thrust. Biotime originally was in cryogenics and had to solve some of the blood-related issues in freezing living tissue. This led to the development of a product that turned out to be not only valuable for cryogenics but also for general use. Before shorting BTIM you should read their responses to critics who appear to be mis-informed (or mal-informed if you ask me). I am long on this one and believe that the huge short interest (about 16-18%) can only drive it up once another critical move develops. Just thoughts for your consideration.

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News